Frank Gray
Overview
Explore the profile of Frank Gray including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
8
Citations
83
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Mariani J, Dobbins R, Heath A, Gray F, Hassman H
Am J Addict
. 2023 Nov;
33(1):8-14.
PMID: 37936553
Background And Objectives: Synthetic opioids, including fentanyl and fentanyl analogs, account for over 70,000 annual overdose deaths in the United States, but there is limited information examining methods of induction...
2.
Moss L, Algera M, Dobbins R, Gray F, Strafford S, Heath A, et al.
PLoS One
. 2022 Jan;
17(1):e0256752.
PMID: 35085249
Background: Opioid-induced respiratory depression driven by ligand binding to mu-opioid receptors is a leading cause of opioid-related fatalities. Buprenorphine, a partial agonist, binds with high affinity to mu-opioid receptors but...
3.
Dong R, Wang H, Li D, Lang L, Gray F, Liu Y, et al.
Drugs R D
. 2019 Jun;
19(3):255-265.
PMID: 31197606
Background: Two phase I studies assessed the pharmacokinetics of buprenorphine, its metabolite norbuprenorphine, and naloxone following administration of buprenorphine/naloxone sublingual tablets in Chinese participants. Methods: In the first phase I,...
4.
Wang X, Jiang H, Zhao M, Li J, Gray F, Sheng L, et al.
Asia Pac Psychiatry
. 2018 Nov;
11(1):e12344.
PMID: 30460781
Introduction: The purpose of the study is to evaluate the efficacy and safety of buprenorphine/naloxone sublingual tablets for the treatment of opioid dependence in Chinese adults. Methods: This multicenter, double-blind,...
5.
Ellis J, van Maurik A, Fortunato L, Gisbert S, Chen K, Schwartz A, et al.
Br J Clin Pharmacol
. 2018 Aug;
85(2):304-315.
PMID: 30161291
Aim: Interleukin (IL)-7 signalling modulates T cell activity and is implicated in numerous autoimmune diseases. The present study investigated the safety, pharmacokinetics, target engagement, pharmacodynamics and immunogenicity of GSK2618960, an...
6.
Wu K, Xu J, Fong R, Yao X, Xu Y, Guiney W, et al.
Int J Clin Pharmacol Ther
. 2016 Oct;
54(12):935-949.
PMID: 27719741
Objective: To evaluate in healthy volunteers the safety, pharmacokinetics (PK), pharmacodynamics (PD), and drug-drug interaction (DDI) potential of GSK2647544, (a selective lipoprotein-associated phospholipase A2 (Lp-PLA2) inhibitor). Methods: Study 1 was...
7.
Xu J, Gray F, Henderson A, Hicks K, Yang J, Thompson P, et al.
Clin Pharmacol Drug Dev
. 2016 Apr;
3(3):170-8.
PMID: 27128606
The tolerability, pharmacokinetics, and pharmacodynamics of single (SD) and repeat (RD) doses of GSK2018682, a selective S1P1 receptor modulator, were evaluated in healthy volunteers. The bioavailability (BA) of different formulations...
8.
Catafau A, Bullich S, Nucci G, Burgess C, Gray F, Merlo-Pich E
J Nucl Med
. 2011 Mar;
52(4):526-34.
PMID: 21421726
Unlabelled: The aim of this study was to assess human striatal dopamine receptor 2 (D(2)) and cortical 5-hydroxytryptamine receptor 2A (5-HT(2A)) occupancy of SB-773812 to demonstrate brain penetration and binding...